CATALYZING RESEARCH TO EXPAND THE CONTRACEPTIVE METHOD MIX - Developing New Contraceptive Technologies and Refining Existing Ones
ESC Congress Library. Halpern V. 05/10/18; 208246; ESC84
Dr. Vera Halpern
Dr. Vera Halpern
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)
Despite the availability of a wide range of contraceptive products including long-acting reversible contraceptives (LARCs), more than 214 million women worldwide want to control their fertility but do not use effective contraceptive methods. For some, access to contraceptive methods is limited. For others, current options do not meet their needs or are unaffordable.  New highly effective, low-cost contraceptives are necessary to fill gaps in the existing contraceptive method mix to ensure broad access to quality, affordable and acceptable products for those most in need. FHI 360, a global leader in contraceptive technology innovation since 1971, develops, evaluates and introduces new contraceptive technologies and refines existing methods. This oral presentation will describe selected research projects from FHI 360's current contraceptive R&D portfolio that spans multiple stages of research, development and introduction with an emphasis on mid- to long-acting methods. Illustrative examples of the projects are provided below. A detailed description of each specific drug delivery technology, as well as the status of each project will be included in the presentation. Early (pre-clinical) development: A collaborative project with the Shanghai Institute of Planned Parenthood Research (Shanghai, China) to develop a 6-month injectable based on the sustained release of levonorgestrel from biodegradable microspheres. Several collaborative projects to develop an 18-month biodegradable implant. Clinical development: FHI 360's research program to develop a 6-month injectable contraceptive based on the existing 3-month DMPA contraceptive injectable. FHI 360's Phase 3 study to evaluate whether the duration of action of Sayana Press® (Pfizer, USA) can be extended from 3 to 4 months. In addition to developing new contraceptive methods, FHI 360 shares experience and knowledge with the global community through the CTI Exchange (, a web portal offering a single point of access for individuals wanting to find or share resources on contraceptive research, development, registration and introduction. In addition to providing a comprehensive resource library, the site houses Calliope, the Contraceptive Pipeline Database (, and CAPRI, the Hormonal Contraceptive Active Pharmaceutical Ingredient Database. Calliope includes information on more than 170 contraceptive products either in various stages of development or offered only in limited markets. CAPRI is a centralized resource of publicly available information on hormonal compounds used in contraceptive products.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings